{
  "id": 7770883,
  "title": "Skyhawk says its Huntington’s drug improved symptoms in extension to Phase 1/2 trial",
  "url": "https://urgent.news/2026/09/16/skyhawk-says-its-huntingtons-drug-improved-symptoms-in-extension-to",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-16T10:56:58.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/skyhawk-says-its-huntingtons-drug-improved-symptoms-in-extension-to-phase-1-2-trial/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Skyhawk Therapeutics’ RNA-splicing candidate for Huntington’s disease improved patients’ symptoms in an early stage-trial, the company said, as it moves to pivotal development. The therapy, called SKY-0515, led to a 1.59-point improvement on a disease ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "Sling gets $123M for Phase 3 trial of ex-Astellas drug in thyroid eye disease",
        "url": "https://urgent.news/2026/09/16/sling-gets-123m-for-phase-3-trial-of-ex-astellas-drug-in-thyroid-eye",
        "published": "2026-09-16T11:00:19.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}